Eisai US Company Profile

Background

Eisai US, established in 1995, operates as the American subsidiary of Tokyo-based Eisai Co., Ltd., a global research and development-driven pharmaceutical company. Guided by the corporate philosophy of "human health care" (hhc), Eisai prioritizes patients and their families, aiming to enhance the benefits that healthcare provides. The company's primary focus lies in neurology and oncology, addressing unmet medical needs through innovative therapies. Eisai's commitment to patient-centric innovation has earned it recognition as one of TIME's 100 Most Influential Companies in 2024.

Key Strategic Focus

Eisai US concentrates on two main therapeutic areas:

• Neurology: Developing treatments for neurological disorders, including Alzheimer's disease and epilepsy.

• Oncology: Advancing therapies for various cancers, leveraging proprietary technologies and strategic collaborations.

The company employs cutting-edge technologies and scientific methodologies to develop innovative treatments, targeting markets with significant unmet medical needs.

Financials and Funding

As of June 2024, Eisai US reported annual revenues of approximately $5 billion, supported by a workforce of around 3,000 employees. The company has secured total funding of $76 million, with the most recent funding round amounting to $40 million. These financial resources are allocated towards research and development initiatives, strategic partnerships, and expanding market presence.

Pipeline Development

Eisai US's pipeline includes several key candidates:

• Leqembi (lecanemab): An Alzheimer's disease treatment developed in collaboration with Biogen. Initially approved by the FDA in January 2023 under the Accelerated Approval Pathway, it received traditional approval in July 2023. In January 2025, the FDA approved a monthly maintenance dosing regimen, enhancing patient convenience.

• Lenvima (lenvatinib): An oncology treatment developed in partnership with Merck, evaluated in combination therapies across multiple tumor types.

These developments underscore Eisai's commitment to addressing critical health challenges through innovative solutions.

Technological Platform and Innovation

Eisai US distinguishes itself through several proprietary technologies and scientific methodologies:

• Antibody-Drug Conjugate (ADC) Technology: Enhances targeted cancer therapies by combining monoclonal antibodies with cytotoxic agents.

• Deep Human Biology Learning (DHBL): Utilizes advanced data analytics and machine learning to understand disease mechanisms and identify potential therapeutic targets.

• Epochal Precision Anti-Cancer Therapeutics (EPAT): Focuses on developing precision medicine approaches in oncology, leveraging unique ADC technology and biospecifics.

These platforms enable Eisai to develop targeted and effective treatments, setting the company apart in the pharmaceutical industry.

Leadership Team

Eisai US's leadership comprises experienced professionals dedicated to advancing the company's mission:

• Ivan Cheung: CEO of Eisai Inc., leading the company's strategic direction and operations in the United States.

• Haruo Naito: Global CEO of Eisai Co., Ltd., overseeing the company's global initiatives and corporate philosophy.

Their combined expertise drives Eisai's commitment to innovation and patient-centric healthcare solutions.

Leadership Changes

In February 2025, Eisai US announced a strategic restructuring, resulting in a reduction of approximately 121 positions across various functions. This initiative aims to streamline operations and enhance the company's focus on core therapeutic areas.

Competitor Profile

Market Insights and Dynamics

The global pharmaceutical market was valued at approximately $1.42 trillion in 2022, with projections to reach $1.57 trillion by 2025. Eisai holds a market share of about 1.5%, competing in a landscape characterized by rapid innovation and technological advancements.

Competitor Analysis

Key competitors include:

• Pfizer: A major player with a market share of 3.6% and annual revenues of $81.3 billion, investing heavily in research and development.

• Novartis: Holding a 3.3% market share with $51.6 billion in annual revenues, focusing on innovative therapies across various disease areas.

• Roche: With a 6.1% market share and $67.5 billion in annual revenues, known for its strong oncology and diagnostics portfolio.

These competitors invest significantly in R&D and marketing, intensifying the competitive landscape for Eisai.

Strategic Collaborations and Partnerships

Eisai US has established several strategic partnerships to enhance its research and development capabilities:

• Biogen: Collaborated on the development and commercialization of Leqembi (lecanemab) for Alzheimer's disease.

• Merck: Partnered to develop combination oncology therapies, resulting in multiple Breakthrough Therapy designations from the FDA.

• Medivir: Formed a Joint Development Committee to provide Lenvima for a study, expanding its oncology research efforts.

These collaborations underscore Eisai's commitment to addressing unmet medical needs through innovative partnerships.

Operational Insights

Eisai US operates several key facilities:

• Nutley, NJ: U.S. Corporate Headquarters, serving as the strategic hub for operations.

• Cambridge, MA: Eisai Center for Genetics Guided Dementia Discovery (G2D2), focusing on breakthrough therapeutics for dementia.

• Exton, PA: Research and development campus specializing in biologics targeting cancers and neurodegenerative diseases.

• Baltimore, MD: